Omalizumab anaphylaxis occurring outside the recommended observation times

In a case-control study in the September 2016 issue of the Journal, Lieberman et al1 describe a series of 30 patients who had anaphylactic reactions associated with omalizumab administration, comparing them with 88 patients who received omalizumab without such reactions. Among their important findings is an increased risk for anaphylaxis to omalizumab in patients who have a history of anaphylaxis to food, medication, or other causes. Such a history would raise the overall 0.2% risk to 0.62%, but in those without such a history would lower the risk to 0.08%.

http://ift.tt/2mEB98G